DCM
LRMR icon

Driehaus Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Driehaus Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.65M Buy
3,163,423
+229,024
+8% +$909K 0.06% 279
2026
Q1 		$13.2M Buy
2,934,399
+2,398,935
+448% +$9.59M 0.1% 253
2025
Q4 		$2.04M Hold
535,464
– – 0.01% 332
2025
Q3 		$1.73M Hold
535,464
– – 0.01% 356
2025
Q2 		$1.55M Buy
535,464
+179,469
+50% +$415K 0.01% 342
2025
Q1 		$765K Sell
355,995
-913,861
-72% -$2.89M 0.01% 355
2024
Q4 		$4.91M Sell
1,269,856
-9,232
-0.7% -$60.9K 0.04% 294
2024
Q3 		$8.38M Sell
1,279,088
-35,018
-3% -$281K 0.07% 244
2024
Q2 		$9.53M Buy
1,314,106
+225,879
+21% +$1.73M 0.09% 223
2024
Q1 		$8.26M Buy
+1,088,227
New +$8.48M 0.08% 249
2022
Q4 		– Sell
-119,223
Closed -$382K – 383
2022
Q3 		$382K Sell
119,223
-91,277
-43% -$229K 0.01% 320
2022
Q2 		$413K Hold
210,500
– – 0.01% 313
2022
Q1 		$853K Hold
210,500
– – 0.01% 330
2021
Q4 		$2.27M Hold
210,500
– – 0.02% 301
2021
Q3 		$2.43M Hold
210,500
– – 0.03% 316
2021
Q2 		$2.07M Hold
210,500
– – 0.03% 311
2021
Q1 		$3.08M Buy
210,500
+100,000
+90% +$1.82M 0.05% 304
2020
Q4 		$2.37M Buy
110,500
+25,500
+30% +$511K 0.04% 283
2020
Q3 		$1.29M Hold
85,000
– – 0.03% 273
2020
Q2 		$1.09M Buy
+85,000
New +$990K 0.03% 282

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Driehaus Capital Management's LRMR Position: Q2 2026 in Review

Driehaus Capital Management increased its Larimar Therapeutics (LRMR) stake by 7.8% in Q2 2026, buying an estimated $909K and bringing the position to 3,163,423 shares worth $9.65M. The position accounts for 0.06% of the portfolio, ranked #279.

Driehaus Capital Management first reported a position in LRMR in Q2 2020 and has held it in 20 quarters since. The position peaked at $13.2M in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Driehaus Capital Management held 3,163,423 shares of Larimar Therapeutics worth $9.65M as of Q2 2026.
  • Driehaus Capital Management bought 229,024 Larimar Therapeutics shares in Q2 2026, an estimated $909K.
  • Larimar Therapeutics made up 0.06% of Driehaus Capital Management's portfolio in Q2 2026, its #279 holding.
  • Driehaus Capital Management first reported a position in Larimar Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • Driehaus Capital Management's Larimar Therapeutics position peaked at $13.2M in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.